A Single-Center, Double-Blind, Randomized, Split-Face, Controlled Clinical Trial to Evaluate and Compare the Efficacy and Tolerance of a Thiamidol-containing Product and Hydroquinone-containing Product When Used by Women with Mild to Moderate Melasma

Published: 21 March 2019| Version 1 | DOI: 10.17632/npxdprzf7f.1
Craig Arrowitz, Andrea Schoelermann, Tobias Mann, Lily Jiang, Teresa Weber, Ludger Kolbe


Individual data set of subjects in this single-center, double-blind, randomized, split-face, controlled clinical trial. The study was conducted over the course of 12 weeks in order to assess the efficacy and tolerance of a Thiamidol-containing topical formulation in comparison to a sunscreen only control (Cell A) and against an over-the-counter (OTC) 2% hydroquinone formula (Cell B) when used by women with bilateral dyspigmentation from melasma. Parameters evaluated (over the course of 12 weeks of use, compared with baseline scores/values and between products): - changes in melasma area and severity index (MASI) - subjective assessment by the subjects - tolerability evaluation (erythema, edema, burning, stining, itching tingling



Biomedical Research